Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Leukemia
Prif Awduron: Gandhi, Ujjawal H, Cornell, Robert F, Lakshman, Arjun, Gahvari, Zhubin J, McGehee, Elizabeth, Jagosky, Megan H, Gupta, Ridhi, Varnado, William, Fiala, Mark A, Chhabra, Saurabh, Malek, Ehsan, Mansour, Joshua, Paul, Barry, Barnstead, Alyssa, Kodali, Saranya, Neppalli, Amarendra, Liedtke, Michaela, Narayana, Swapna, Godby, Kelly N, Kang, Yubin, Kansagra, Ankit, Umyarova, Elvira, Scott, Emma C, Hari, Parameswaran, Vij, Ravi, Usmani, Saad Z, Callander, Natalie S, Kumar, Shaji K, Costa, Luciano J
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820050/
https://ncbi.nlm.nih.gov/pubmed/30858549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0435-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg